Xenon Pharmaceuticals (NASDAQ:XENE) Downgraded by BidaskClub

Xenon Pharmaceuticals (NASDAQ:XENE) was downgraded by equities researchers at BidaskClub from a “buy” rating to a “hold” rating in a report released on Tuesday, BidAskClub reports.

Several other research analysts also recently commented on XENE. Zacks Investment Research downgraded Xenon Pharmaceuticals from a “buy” rating to a “hold” rating in a research report on Saturday, February 23rd. Stifel Nicolaus reaffirmed a “buy” rating and issued a $18.00 price target (down from $21.00) on shares of Xenon Pharmaceuticals in a research report on Friday, March 29th. One analyst has rated the stock with a sell rating, one has issued a hold rating, two have given a buy rating and one has assigned a strong buy rating to the stock. The company currently has a consensus rating of “Buy” and an average target price of $15.00.

XENE opened at $8.97 on Tuesday. The company has a debt-to-equity ratio of 0.18, a current ratio of 17.57 and a quick ratio of 17.57. The company has a market capitalization of $233.76 million, a P/E ratio of -6.74 and a beta of 1.44. Xenon Pharmaceuticals has a twelve month low of $5.41 and a twelve month high of $15.92.

Xenon Pharmaceuticals (NASDAQ:XENE) last issued its quarterly earnings results on Tuesday, May 7th. The biopharmaceutical company reported ($0.42) EPS for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.36) by ($0.06). Equities analysts expect that Xenon Pharmaceuticals will post -1.88 earnings per share for the current year.

A number of hedge funds and other institutional investors have recently modified their holdings of XENE. Schonfeld Strategic Advisors LLC boosted its holdings in shares of Xenon Pharmaceuticals by 2.0% during the 1st quarter. Schonfeld Strategic Advisors LLC now owns 500,000 shares of the biopharmaceutical company’s stock valued at $5,080,000 after acquiring an additional 9,942 shares in the last quarter. Altshuler Shaham Ltd boosted its holdings in shares of Xenon Pharmaceuticals by 46.5% during the 1st quarter. Altshuler Shaham Ltd now owns 143,607 shares of the biopharmaceutical company’s stock valued at $1,459,000 after acquiring an additional 45,600 shares in the last quarter. Altrinsic Global Advisors LLC boosted its holdings in shares of Xenon Pharmaceuticals by 6.7% during the 1st quarter. Altrinsic Global Advisors LLC now owns 160,000 shares of the biopharmaceutical company’s stock valued at $1,626,000 after acquiring an additional 10,000 shares in the last quarter. Northern Trust Corp boosted its holdings in shares of Xenon Pharmaceuticals by 97.6% during the 1st quarter. Northern Trust Corp now owns 24,202 shares of the biopharmaceutical company’s stock valued at $246,000 after acquiring an additional 11,956 shares in the last quarter. Finally, Knott David M boosted its holdings in shares of Xenon Pharmaceuticals by 3.5% during the 1st quarter. Knott David M now owns 179,390 shares of the biopharmaceutical company’s stock valued at $1,823,000 after acquiring an additional 6,000 shares in the last quarter. 68.83% of the stock is currently owned by institutional investors.

About Xenon Pharmaceuticals

Xenon Pharmaceuticals, Inc engages in discovering and developing therapeutics to improve the lives of patients with neurological disorders. It focuses on the treatment of epilepsy. Its products include XEN496, XEN1101, XEN901, and XEN007. The company was founded by Simon Neil Pimstone, Johannes J. P.

Featured Story: How do investors use RSI to grade stocks?

Receive News & Ratings for Xenon Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Xenon Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.